Global Disposable Liquid Storage Bags Market Research: Market Size, Growth Trends, and Competitive Landscape (Single-Use Bioprocessing Solutions) – QYResearch

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Disposable Liquid Storage Bags – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Disposable Liquid Storage Bags market, including market size, share, demand, industry development status, and forecasts for the next few years.

For biopharmaceutical manufacturers, cell therapy developers, and contract research organizations seeking to eliminate cross-contamination risks, reduce cleaning validation costs, and accelerate batch turnaround times, understanding the market size, material specification standards, and regulatory compliance requirements of disposable liquid storage bags is essential. Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)

---

Market Valuation and Growth Trajectory (2026-2032)

The global Disposable Liquid Storage Bags market was valued at approximately USD 1.8 billion in 2025 and is projected to reach USD 3.4 billion by 2032, registering a compound annual growth rate (CAGR) of 9.6% during the forecast period. In 2025, global consumption of disposable liquid storage bags exceeded 85 million units, with average pricing varying significantly by configuration: 2D liner bags (USD 15–40 per unit), 3D storage bags (USD 45–120 per unit), and cell culture bags (USD 80–300 per unit). Gross profit margins range from 25% to 45%, influenced by film material complexity (single-layer vs. multi-layer co-extrusion), customization (port fittings, tubing assemblies, gamma irradiation sterilization), and regulatory compliance (USP Class VI, ISO 10993, extractables and leachables testing).

Disposable liquid storage bags are single-use, sterile, flexible containment systems used in biopharmaceutical manufacturing, medical fluid management, cell and gene therapy, and laboratory research. Constructed from multi-layer plastic films (typically polyethylene, ethylene vinyl alcohol, or multilayer co-extrusions), these bags provide a sterile, closed environment for storing, mixing, and transporting critical fluids including cell culture media, buffer solutions, bulk drug substances, blood products, intravenous fluids, breast milk, and biological samples. Key advantages over traditional stainless steel or glass containers include elimination of cleaning and sterilization validation (reducing turnaround time from days to hours), lower capital investment, reduced risk of cross-contamination, and greater flexibility for batch sizes and product changeovers.

Core Industry Value Proposition and Market Drivers

The primary pain points addressed by disposable liquid storage bags include: (1) high cleaning and sterilization costs for reusable stainless steel vessels (typically 6–12 hours of CIP/SIP cycles plus validation documentation), (2) cross-contamination risk between batches of different products (particularly critical for cell therapy and multi-product facilities), (3) capital-intensive stainless steel infrastructure (tanks, piping, clean-in-place systems) requiring large footprint and upfront investment, and (4) inflexibility for variable batch sizes in contract manufacturing and clinical trial production. Key drivers for market share expansion include:

• Biopharmaceutical Industry Growth: Global biopharmaceutical market projected to reach USD 650 billion by 2032, with 40% of biologics manufacturing utilizing single-use technologies for upstream and downstream processing.
• Cell and Gene Therapy Expansion: Personalized therapies requiring dedicated, disposable components for each patient batch (autologous cell therapy manufacturing demands single-use systems to prevent cross-patient contamination). Over 2,000 cell and gene therapy clinical trials active globally (2026).
• Vaccine and Pandemic Preparedness: Demand for rapid manufacturing scale-up (disposable systems enable faster facility deployment – 12–18 months vs. 36–48 months for stainless steel facilities). Post-pandemic stockpiling of single-use consumables.
• Contract Manufacturing and CDMO Growth: CDMOs require flexible, multi-product platforms – single-use bags enable rapid changeover between client projects without cleaning validation delays.
• Regulatory Preference for Closed Systems: USP Chapter (proposed update 2026) encourages closed, single-use systems for aseptic processing to reduce contamination risk.

Upstream Supply Chain and Material Technology

The industry chain for disposable liquid storage bags comprises three distinct tiers:

Upstream – Raw Materials and Components:

• Multi-Layer Films: Typically 3–7 layer co-extrusions with specific functional layers:
  • Fluid Contact Layer: Ultra-low density polyethylene (ULDPE) or ethylene vinyl acetate (EVA) – USP Class VI, ISO 10993, non-cytotoxic, low extractables.
  • Barrier Layer: EVOH (ethylene vinyl alcohol) for oxygen and moisture barrier – critical for oxygen-sensitive biologics (antibodies, cell culture media, blood products).
  • Structural Layer: Linear low-density polyethylene (LLDPE) for mechanical strength, puncture resistance, and drop-test integrity.
  • Outer Layer: LLDPE or nylon for abrasion resistance and protection during handling.
• Ports and Tubing Assemblies: Medical-grade platinum-cured silicone tubing, C-Flex, or thermoplastic elastomer (TPE). Barbed or sterile-welded connectors (male/female luer, MPC, Tri-Clamp compatible). Custom configurations (2–6 ports per bag).
• Fittings and Closures: Injection molded polycarbonate or polypropylene ports, caps, and septa for needle-free sampling.
• Gamma Irradiation Services: Sterilization to 25–40 kGy SAL (sterility assurance level) of 10^-6. Dose validation per ISO 11137.

Midstream – Bag Manufacturing:
Manufacturers produce bags through film extrusion, sealing (impulse, radio frequency, or hot bar welding), port insertion, leak testing (100% visual or pressure decay), gamma irradiation (in contracted or owned facilities), and double-bagging for aseptic transfer into cleanrooms. Key quality parameters include film thickness uniformity (±5%), seal strength (minimum 20 N/15mm peel), extractables and leachables profile (E&L per BPOG or USP 665/1665 guidelines), integrity testing (no leaks at 0.5–1.0 psi pressure hold), and bioburden/endotoxin testing (≤0.5 EU/mL for pharmacopoeial applications).

Downstream – End-User Distribution:

• Biopharmaceutical Manufacturers: Largest segment – media and buffer preparation, bulk drug substance storage, intermediate hold steps, final product formulation and freezing.
• Cell Therapy and Gene Therapy Developers: Patient-specific cell culture bags, cryostorage bags, wash and harvest bags.
• Hospitals and Blood Banks: Blood collection and storage bags (whole blood, packed red cells, platelets, plasma), IV fluid bags, urine collection bags, breast milk storage bags.
• Contract Development and Manufacturing Organizations (CDMOs): Flexible, multi-client facilities requiring large volumes of single-use bags for various campaigns.
• Laboratories and Research Institutions: Cell culture media storage, bioreactor feed bags, waste collection, biological sample storage.

Regional Market Dynamics and Policy Drivers (Last 6 Months)

North America (Largest Market Share, ~42% of global revenue):
The U.S. dominates disposable liquid storage bag consumption, driven by the world’s largest biopharmaceutical industry (approximately 45% of global biologics production). Key policy drivers include the FDA’s “Advancing Continuous Manufacturing” guidance (December 2025) encouraging single-use technologies for flexible continuous processing. The Biosimilars Action Plan (updated 2026) has accelerated biosimilar approvals (35 approvals in 2025), each requiring dedicated single-use components for clinical and commercial manufacturing. CAR-T and cell therapy hubs in Boston, San Francisco, Philadelphia, and Maryland drive demand for custom-designed cell culture and cryostorage bags.

Europe (Quality-Focused, ~30% market share):
Germany, Switzerland, France, and the UK lead in high-quality single-use bioprocessing components. EMA’s Annex 1 revision (2022, fully enforced 2025) emphasizes closed systems and contamination control strategy (CCS) – disposable liquid storage bags are explicitly cited as preferred technology for multi-product facilities to prevent cross-contamination. European biopharma CDMOs (Lonza, Recipharm, Catalent) are expanding single-use capacities. EU MDR and IVDR transition timelines (full compliance 2026–2027) affect bag manufacturers supplying medical device or IVD segments.

Asia-Pacific (Fastest-Growing Region, CAGR 12.3%):
China, South Korea, Singapore, and India drive the highest growth rate globally. China’s biopharmaceutical industry is expanding at 15% annually, with over 500 biologics INDs filed in 2025. Domestic bag manufacturers (Shanghai LePure Biotech, Austar Life Technology, Gleiser Life Technology) are gaining market share through cost advantages (pricing 30–40% below Western competitors) and government procurement preferences. India’s “Pharma Vision 2030″ includes targets for biologics exports (USD 25 billion by 2030), driving single-use adoption. Southeast Asian CDMOs (Singapore, Malaysia) are attracting Western biopharma clients seeking regional manufacturing diversification.

Case Example – CDMO Efficiency Improvement:

A global CDMO (contract development and manufacturing organization) with facilities in the U.S. and Europe transitioned 80% of its media and buffer preparation from stainless steel vessels to disposable liquid storage bags (3D, 200–1,000 L configurations) in Q4 2025, covering 12 multi-product client campaigns. Outcomes over 6 months included:

• Batch turnaround time reduction: From 48 hours (including CIP/SIP and validation) to 4 hours (bag replacement and integrity check) – 92% reduction.
• Water and energy savings: Eliminated 1.2 million liters of WFI (water for injection) and 450,000 kWh annually – carbon footprint reduction of 210 metric tons CO₂e.
• Capital expenditure avoidance: USD 8.5 million saved by deferring stainless steel tank expansion.
• Changeover efficiency: Product changeover from monoclonal antibody to fusion protein reduced from 5 days to 6 hours.
• Quality improvement: Zero cross-contamination events in client campaigns (vs. 2 events in previous 12 months with stainless steel changeover cleaning gaps).
• E&L compliance: Full extractables and leachables (E&L) characterization per BPOG guidelines provided by bag supplier, accepted by four regulatory authorities for clinical trial applications.

Technology Segmentation and Product Differentiation

The market is segmented as below:

By Key Players (Global Leaders and Regional Specialists):
Sartorius, Shanghai LePure Biotech Co., Ltd, Johnson & Johnson, Lampire Biological Laboratories, Medline Industries, Medtronic, Inc., Lansinoh Laboratories, Inc., CellGenix, Macopharma, Austar Life Technology Co., Ltd., Gleiser Life Technology Co., Ltd., Ameda, Philips Healthcare, Siemens Healthcare, GE Healthcare (now part of Cytiva), Cardinal Health, 3M, RIM Bio, Cell Therapy (part of Miltenyi Biotec), Origen Biomedical, Miltenyi Biotec.

By Type (Bag Configuration):

• Liner Bag: Flexible film bag used as disposable liner within rigid stainless steel or plastic outer containers (drums, bins, IBCs – intermediate bulk containers). Typically 50–1,000 L capacity. Dominant in buffer preparation and bulk intermediate storage. Largest segment by volume (~40%).
• 2D Type Liquid Storage Bag: Flat, pillow-style bag (two-dimensional) – 0.1–50 L capacities. Used for small-volume media, buffers, sera, supplements, and bioreactor feed bags. Ideal for laboratory and clinical-scale production. High-growth segment for cell therapy applications.
• 3D Type Liquid Storage Bag: Three-dimensional bag with welded bottom gusset – 50–3,000 L capacities. Self-supporting when filled, fits into rigid outer containers (drums, pallet tanks). Dominant for commercial-scale media, harvest, and intermediate hold. Largest segment by revenue (~45%).
• Cell Culture Bag: Specialized bag with gas-permeable film (typically EVA or fluorinated ethylene propylene – FEP) for adherent or suspension cell culture. Incubator-compatible, CO₂/oxygen transfer optimized. Used for T-cell expansion, stem cell culture, vaccine production, and hybridoma growth. Fastest-growing segment (CAGR 14%).

By Application:

• Medical: Blood collection (blood bags), IV fluid bags, breast milk storage, urine collection, enteral feeding bags (~30% of market revenue).
• Biology/Biopharma: Cell culture media storage, buffer preparation, bulk drug substance storage, harvest hold, cryopreservation (cryo-bags), bioreactor feed bags, waste collection. Largest segment (~55% of market revenue).
• Chemical: Storage of chemical intermediates, reagents, cleaning solutions, solvents. Smaller segment (~8%).
• Others: Food and beverage (aseptic storage of juices, concentrates), cosmetics, veterinary, environmental sampling (~7%).

Industry Layering Perspective: Single-Use vs. Reusable Storage Systems

An original analytical lens emerges when comparing disposable liquid storage bags to traditional stainless steel or glass storage across discrete and continuous manufacturing models:

Key Insight: Disposable liquid storage bags have become the default choice for biopharmaceutical manufacturing volumes up to 3,000 L (batch sizes typical for monoclonal antibodies, cell therapies, and clinical trial materials). Above 3,000 L, stainless steel retains cost advantages for large-scale commercial production (10,000–25,000 L bioreactors). However, the trend toward continuous manufacturing and modular facilities is extending the addressable range of single-use systems – new 5,000 L bag designs (Sartorius Flexsafe 5X, Cytiva Xcellerex XDUO) are emerging.

Future Trends: Higher-Volume Bags, E&L Standardization, Recyclable Films

Over the forecast period 2026–2032, disposable liquid storage bags will evolve along four strategic vectors:

Larger Capacity Bags (5,000–10,000 L): Development of 5,000–10,000 L single-use bags for commercial-scale manufacturing – addressing the “capacity gap” between single-use (max 3,000 L historically) and stainless steel (10,000 L+). Early commercialized: Sartorius Flexsafe 5X (5,000 L), Cytiva Xcellerex XDUO 5,000 (5,000 L). Challenges include film structural integrity (hydrostatic pressure at 5,000 L = 5 metric tons), handling and ergonomics, and gamma irradiation uniformity.

Extractables and Leachables (E&L) Standardization: Industry-wide adoption of BPOG (BioProcess Systems Alliance) E&L test methods and reporting standards (2026 update includes new database for 25 common single-use components). Regulatory expectations for leachable monitoring during routine production (per USP 665/1665). Suppliers offering pre-qualified, “off-the-shelf” E&L packages (reducing client validation burden from 6–9 months to 4–6 weeks).

Recyclable and Bio-Based Films: Development of mono-material PE-based films (without EVOH barrier layers for applications not requiring extreme oxygen barrier) that are recyclable via conventional polyethylene recycling streams. Bio-based polyethylene (from sugarcane) for reduced carbon footprint (50–60% lower CO₂e vs. petrochemical PE). Challenges include maintaining EVOH-level oxygen barrier (Mono-material PE with SiOx coating achieves OTR 5–10 cm³/m²/day vs. EVOH <1 – acceptable for many non-O₂-sensitive fluids).

Smart Bags with Integrated Sensors: Embedding thin-film sensors (temperature, pH, dissolved oxygen, pressure) within bag film layers – providing real-time monitoring of stored fluid conditions without breaching sterile barrier. RFID/NFC tags for tracking and chain-of-custody documentation (enabling digital batch records). Commercial pilots underway (Sartorius Smart Flexsafe, Cytiva Ready-to-Use Sensor Ports).

Exclusive Observation: The Shift from Off-the-Shelf to Co-Developed, Application-Specific Bags

A notable trend emerging in 2025–2026 is the transition from standard catalog bag configurations to co-developed, application-specific designs through supplier-client partnerships:

• Cell Therapy Customization: Autologous cell therapy manufacturers require patient-specific bag sets (single batch per patient) with unique tubing lengths, port configurations, and sample ports matched to closed automated cell processing systems (Miltenyi CliniMACS, Lonza Cocoon). Bag suppliers now embed application engineers within cell therapy client sites for rapid design iteration.
• Cryopreservation Optimization: Bags for cryopreservation of cell therapy products require specialized film formulations (fluorinated ethylene propylene – FEP) that remain flexible at −196°C (liquid nitrogen), high post-thaw integrity, and certified low leachables under cryogenic conditions. Suppliers (OriGen, Sartorius, Macopharma) offer application-specific cryo-bags with validated freeze-thaw cycles.
• High-Viscosity Fluids: For concentrated protein formulations (>150 mg/mL) and gene therapy vectors, bag films must withstand elevated pressure (peristaltic pumping, pressure-based filtration). Co-developed high-strength films with enhanced burst strength and seal integrity.

Companies investing in co-development capabilities (dedicated application scientists, rapid prototyping, small-scale production for clinical trials) will capture higher market share and margins compared to catalog-focused competitors.

Technical Challenges and Mitigation Strategies

Despite clear bioprocessing advantages, adoption faces four persistent technical challenges:

• Extractables and Leachables (E&L): All plastic films and components release chemical compounds into stored fluids over time – potentially toxic to cells or compromising drug product quality. Mitigation includes rigorous E&L testing per BPOG best practices (simulating worst-case process conditions: time, temperature, agitation, solvent composition). Use of certified “low E&L” film formulations (e.g., Sartorius Flexsafe film family with >200 compounds characterized). Risk-based approach: analytical evaluation threshold (AET) per PQRI recommendation.
• Film Integrity and Leak Risk: Pinholes, seal defects, or damage during handling cause contamination or product loss. Mitigation includes 100% leak testing for critical applications (pressure decay, bubble emission, or high-voltage leak detection for conductive films). Integrity testing post-sterilization (gamma irradiation can weaken seals if not properly validated). Design of secondary overwrap bags for critical aseptic transfers (double-bag systems widely used).
• Biological Compatibility: Film surfaces must not adsorb product components (e.g., proteins, antibodies, viral vectors) – adsorption causes yield loss (5–25% reported). Mitigation includes surface modification (hydrophilic coatings, low-protein-binding formulations) and use of film materials with documented low adsorption (EVA, ULDPE, FEP). Pre-use bag rinsing (with product formulation buffer) to saturate adsorption sites.
• Environmental Sustainability: Disposable bags generate significant plastic waste (estimates: 5–10 kg of plastic waste per 1,000 L of bioprocess volume). Mitigation includes recycling programs (bag manufacturers offering take-back for cleaning, grinding, and downcycling into lower-grade plastic products), reduced film thickness (without compromising integrity), and development of bio-based and recyclable film formulations. Industry working groups (BPOG Single-Use Sustainability) developing end-of-life guidance.

Recent Industry Developments (Last 6 Months, 2025–2026):

• Regulatory: USP published new chapter on “Single-Use Systems in Biopharmaceutical Manufacturing” (draft for comment, February 2026) – providing guidance on qualification, E&L testing, integrity testing, and operational controls. Expected final 2027.
• Corporate Commitment: Sartorius announced January 2026 expansion of its single-use film manufacturing capacity in Massachusetts (USD 120 million investment), increasing annual bag output by 60% to meet demand.
• Technology: Cytiva launched “ReadyToProcess WAVE 2D Rocking Bags” (November 2025) – pre-filled with cell culture media and cells, enabling rapid initiation of perfusion cultures without aseptic filling.
• M&A: Shanghai LePure Biotech acquired Gleiser Life Technology (December 2025) – consolidating second-largest domestic bag manufacturer in China, now controlling approximately 35% of China’s disposable bag market share.

Conclusion and Strategic Outlook

With sustained growth in biologics, cell and gene therapies, CDMO outsourcing, and vaccine manufacturing, the disposable liquid storage bags market is positioned for robust growth and continued innovation. Future competitive differentiation will hinge on:

• Material science leadership (low E&L films, recyclable structures, cryo-compatible formulations)
• Custom co-development capabilities (application-specific designs, rapid prototyping, clinical-to-commercial scale-up)
• Regulatory and quality expertise (USP/ISO/BPSG compliance, comprehensive E&L documentation, validation support)
• Global manufacturing footprint (regional capacity for supply security and reduced logistics costs)
• Sustainability initiatives (take-back recycling programs, bio-based content, reduced film thickness)

Bag manufacturers investing in co-development partnerships, E&L science, and sustainable film solutions are expected to capture premium pricing and expand market share at the expense of commodity-focused suppliers lacking regulatory and technical depth.

---

Contact Us:
If you have any queries regarding this report or would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp